Next Article in Journal
SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination
Next Article in Special Issue
Decreased Expression of CD314 by NK Cells Correlates with Their Ability to Respond by Producing IFN-γ after BCG Moscow Vaccination and Is Associated with Distinct Early Immune Responses
Previous Article in Journal
Designing a Multi-Epitope Subunit Vaccine against VP1 Major Coat Protein of JC Polyomavirus
Previous Article in Special Issue
Viral Pneumonia during the COVID-19 Pandemic, 2019–2021 Evoking Needs for SARS-CoV-2 and Additional Vaccinations
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 7
10.3390/vaccines11071183
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees

by
Letícia Carrijo Masson
1,
Carolina do Prado Servian
1,
Vitor Hugo Jardim
1,
Déborah dos Anjos
1,
Miriam Leandro Dorta
1,
João Victor Batalha-Carvalho
2,
Ana Maria Moro
2,3,
Pedro Roosevelt Torres Romão
4,
Menira Souza
1,
Fabiola Souza Fiaccadori
1 and
Simone Gonçalves Fonseca
1,3,*
1
Departamento de Biociências e Tecnologia, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia 74605-050, GO, Brazil
2
Laboratório de Biofármacos, Instituto Butantan, São Paulo 05503-900, SP, Brazil
3
Instituto de Investigação em Imunologia, Instituto Nacional de Ciência e Tecnologia (iii-INCT), Goiânia 74605-050, GO, Brazil
4
Laboratório de Imunologia Celular e Molecular, Programa de Pós-Graduação em Ciências da Saúde, Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre 90050-170, RS, Brazil
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(7), 1183; https://doi.org/10.3390/vaccines11071183
Submission received: 21 May 2023 / Revised: 21 June 2023 / Accepted: 25 June 2023 / Published: 30 June 2023
(This article belongs to the Special Issue Safety and Effectiveness of COVID-19 Vaccines on COVID-19 Infection and Its Long-Term Consequences)
Browse Figures
Review Reports Versions Notes

Abstract

Immune responses after COVID-19 vaccination should be evaluated in different populations around the world. This study compared antibody responses induced by ChAdOx1 nCoV-19, CoronaVac, and BNT162b2 vaccines. Blood samples from vaccinees were collected pre- and post-vaccinations with the second and third doses. The study enrolled 78 vaccinees, of whom 62.8% were women, with the following median ages: 26 years—ChAdOx1 nCoV-19; 40 years—CoronaVac; 30 years—BNT162b2. Serum samples were quantified for anti-RBD IgG and anti-RBD IgA and anti-spike IgG by ELISA. After two vaccine doses, BNT162b2 vaccinees produced higher levels of anti-RBD IgA and IgG, and anti-spike IgG compared to ChAdOx1 nCoV-19 and CoronaVac vaccinees. The third dose booster with BNT162b2 induced higher levels of anti-RBD IgA and IgG, and anti-spike IgG in CoronaVac vaccinees. Individuals who reported a SARS-CoV-2 infection before or during the study had higher anti-RBD IgA and IgG production. In conclusion, two doses of the studied vaccines induced detectable levels of anti-RBD IgA and IgG and anti-spike IgG in vaccinees. The heterologous booster with BNT162b2 increased anti-RBD IgA and IgG and anti-spike IgG levels in CoronaVac vaccinees and anti-RBD IgA levels in ChAdOx1 nCoV-19 vaccinees. Furthermore, SARS-CoV-2 infection induced higher anti-RBD IgA and IgG levels in CoronaVac vaccinees.
Keywords: vaccine; COVID-19; humoral immune response; RBD; spike; antibodies vaccine; COVID-19; humoral immune response; RBD; spike; antibodies

Share and Cite

MDPI and ACS Style

Masson, L.C.; Servian, C.d.P.; Jardim, V.H.; dos Anjos, D.; Dorta, M.L.; Batalha-Carvalho, J.V.; Moro, A.M.; Romão, P.R.T.; Souza, M.; Fiaccadori, F.S.; et al. Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees. Vaccines 2023, 11, 1183. https://doi.org/10.3390/vaccines11071183

AMA Style

Masson LC, Servian CdP, Jardim VH, dos Anjos D, Dorta ML, Batalha-Carvalho JV, Moro AM, Romão PRT, Souza M, Fiaccadori FS, et al. Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees. Vaccines. 2023; 11(7):1183. https://doi.org/10.3390/vaccines11071183

Chicago/Turabian Style

Masson, Letícia Carrijo, Carolina do Prado Servian, Vitor Hugo Jardim, Déborah dos Anjos, Miriam Leandro Dorta, João Victor Batalha-Carvalho, Ana Maria Moro, Pedro Roosevelt Torres Romão, Menira Souza, Fabiola Souza Fiaccadori, and et al. 2023. "Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees" Vaccines 11, no. 7: 1183. https://doi.org/10.3390/vaccines11071183

APA Style

Masson, L. C., Servian, C. d. P., Jardim, V. H., dos Anjos, D., Dorta, M. L., Batalha-Carvalho, J. V., Moro, A. M., Romão, P. R. T., Souza, M., Fiaccadori, F. S., & Fonseca, S. G. (2023). Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees. Vaccines, 11(7), 1183. https://doi.org/10.3390/vaccines11071183

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop